Source:http://linkedlifedata.com/resource/pubmed/id/15163894
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2004-5-27
|
| pubmed:abstractText |
We evaluated phenotypic and functional parameters of immune restoration of 27 HIV-infected patients on highly active antiretroviral therapy (HAART) (HIV-cases) with HIV-RNA levels below detectable limits at least during 18 months, and CD4+ cell per microliter higher than 500 at the moment of the study and lower than 300 anytime before. These patients were compared with 11 HIV-controls that never had less than 500 CD4+ cell per microliter and 20 healthy-controls (HIV seronegative subjects) in a cross-sectional study. HIV-cases had lower counts of naïve CD4+ than HIV-controls and healthy-controls. HIV-patients (both HIV-cases and HIV-controls) showed higher values of naïve and memory CD8+ counts than healthy-controls. TREC-bearing cell levels were significantly lower in HIV-cases than in healthy-controls. Peripheral blood mononuclear cells (PBMC) cultures, HIV-cases had lower values in proliferation to streptokinase (SK) and tetanus toxin (TT) than in healthy-controls. HIV-cases had lower IFN-gamma and higher IL-5 production with pokeweed than healthy-controls ( P < 0.01). However, IL-5 production of HIV-cases after TT stimulation was lower than in HIV-controls and healthy-controls. Total IgG and IgG1 levels were significantly higher in HIV-cases than in HIV-controls and healthy-controls. Also, IgM levels were significantly higher in HIV-cases than in healthy-controls. Nevertheless, IgG2 levels were significantly lower in HIV-cases and HIV-controls than in healthy-controls. The levels of specific Igs antipneumococcal capsular polysaccharide and TT were significantly lower in HIV-cases than in healthy-controls. HIV-patients with a previous state of severe-moderate immunosuppression normalizing their CD4+ counts have a incomplete immune reconstitution after HAART. Long-term consequences of this subclinical immune deficiency remain to be determined.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
0271-9142
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
24
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
379-88
|
| pubmed:dateRevised |
2008-11-21
|
| pubmed:meshHeading |
pubmed-meshheading:15163894-Adult,
pubmed-meshheading:15163894-Aged,
pubmed-meshheading:15163894-Antiretroviral Therapy, Highly Active,
pubmed-meshheading:15163894-CD4 Lymphocyte Count,
pubmed-meshheading:15163894-Case-Control Studies,
pubmed-meshheading:15163894-Cell Proliferation,
pubmed-meshheading:15163894-Cross-Sectional Studies,
pubmed-meshheading:15163894-Female,
pubmed-meshheading:15163894-HIV Infections,
pubmed-meshheading:15163894-Humans,
pubmed-meshheading:15163894-Immunity,
pubmed-meshheading:15163894-Immunoglobulin G,
pubmed-meshheading:15163894-Immunosuppression,
pubmed-meshheading:15163894-Interferon-gamma,
pubmed-meshheading:15163894-Interleukin-5,
pubmed-meshheading:15163894-Lymphoid Tissue,
pubmed-meshheading:15163894-Lymphopoiesis,
pubmed-meshheading:15163894-Male,
pubmed-meshheading:15163894-Middle Aged,
pubmed-meshheading:15163894-Regeneration
|
| pubmed:year |
2004
|
| pubmed:articleTitle |
Immunity in HIV-1-infected adults with a previous state of moderate-severe immune-suppression and more than 500 CD4+ T cell after highly active antiretroviral therapy.
|
| pubmed:affiliation |
Laboratorio de Immuno-Biología Molecular, Hospital General Universitario Gregorio Marañón, C/Doctor Esquerdo 46, 28007 Madrid, Spain.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|